Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
2,505.8
35.2 (1.42%)

 

  • STI Straits Times Index
    2,505.8
    35.2 (1.42%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,341.7
    -
    Index delayed 15 minutes
  • HSI Hang Seng Index
    23,749.1
    -
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,764.0
    -16.7 (-0.60%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    18,980.1
    403.8 (2.17%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    4,811.8
    -
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 0.2M
  • Value: 0.6M
  • Rise: -
  • Fall: -
  • Unch: 811

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Rex Intl0.104+0.002
ESR-REIT0.255+0.010
CapitaMall Trust1.650+0.030
Thomson Medical0.055+0.001
Genting Sing0.710+0.020
Singtel2.630+0.020
IPS Securex0.054+0.001
Mapletree Log Tr1.590+0.040
Keppel DC Reit2.390+0.040
NetLink NBN Tr0.925+0.010

World Indices

World Indices
Name Last Change
Nasdaq 7,913.2 +540.2
HSI 23,749.1
HSCEI 9,652.3
Jakarta 4,811.8
Nikkei 225 19,020.3 +444.0
SSE Comp 2,764.0 -16.6
Shanghai A 2,896.6 -17.5
Shanghai B 216.0 -0.8
KOSPI 1,816.1 +24.2

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

MESOBLAST LTD SPON ADR EACH REP 5 SHS MESOBLAST LIMITED SPONSORED ADR
Updated on 03 Apr 2020 (End of trading day)
Last (USD): 4.200 Change: -0.320 High: 4.490 Remarks: -
Change (%): -7.08 Low: 4.100
Open 4.480 Yesterday's Close 4.5200000000000005
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 137,766 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.83576 Trailing EPS (USD) e -0.70800 NAV (USD) b 4.6606
PE a - Trailing PE f - Price / NAV b 0.9012
Dividend (USD) d - Cash In Hand (USD) g 0.7570 Issued & Paid-up Shares c 107,455,000
Dividend Yield (%) d - Price / Cash In Hand g 5.548 Treasury Shares h 700,000
Beta - 75 Daysi 1.208 R-Squared - 75 Days(%)i 32.13 Market Cap (M) 451.311
Beta - 500 Daysi 0.725 R-Squared - 500 Days (%)i 7.16 Enterprise Value (M) 464.261
Piotroski F Score 0 Exchange Code MESO Par Value ( $ ) n.a.
52 Weeks Volatility (%) 77.73 Free Float (%) 93.4
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 18 Mar 2020.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 28 Mar 2018.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference MESOBLAST LTD SPON ADR EACH REP 5 SHS NASDAQ 451.311 - - 0.9012 -
Industry Biotechnology NASDAQ 2,257.734 257.736 243.454 5.3927 0.810
Local Peer AMGEN INC NASDAQ 121,152.256 14.433 15.449 12.5248 2.744
Local Peer GILEAD SCIENCES INC NASDAQ 98,467.172 18.051 18.282 4.3715 2.968
Local Peer VERTEX PHARMACEUTICAL NASDAQ 61,786.395 29.473 52.503 10.1535 -
Local Peer REGENERON PHARMACEUTICALS INC NASDAQ 54,275.052 22.204 25.652 4.8942 -
Local Peer BIOGEN INC NASDAQ 52,307.973 11.806 8.883 3.9202 -
Local Peer ILLUMINA INC NASDAQ 38,734.500 46.894 38.657 8.3968 -
Local Peer SEATTLE GENETICS INC NASDAQ 20,070.013 - - 10.6966 -
Local Peer ALEXION PHARMACEUTICAL INC NASDAQ 19,937.917 256.934 8.293 1.7688 -
Local Peer INCYTE CORPORATION NASDAQ 17,036.426 155.593 38.121 6.5565 -
Local Peer BIOMARIN PHARMACEUTICAL NASDAQ 15,151.568 - - 4.8526 -
Local Peer GALAPAGOS NV SPON ADR REPR 1 ORD SHS NASDAQ 12,333.111 - 39.738 4.4621 -
Local Peer ALNYLAM PHARMACEUTICALS INC NASDAQ 11,965.279 - - 8.3168 -
Other Local Peers BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), MODERNA INC (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), EXACT SCIENCES CORP (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), 10X GENOMICS INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), EXELIXIS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), FIBROGEN INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), UNIQURE N.V. (NASDAQ), KODIAK SCIENCES INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), ALECTOR INC (NASDAQ), XENCOR INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), VIELA BIO INC (NASDAQ), ARVINAS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), INSMED INC (NASDAQ), EPIZYME INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), REGENXBIO INC (NASDAQ), CORTEXYME INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), VERACYTE INC (NASDAQ), NEXTCURE INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), BLACK DIAMOND THERAPEUTICS INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), BEAM THERAPEUTICS INC (NASDAQ), NOVAVAX INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), CYTOKINETICS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), OMEROS CORP (NASDAQ), PASSAGE BIO INC (NASDAQ), RETROPHIN INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), IMMUNOGEN INC (NASDAQ), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), TRANSLATE BIO INC (NASDAQ), COMPUGEN (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), ARDELYX INC (NASDAQ), AVROBIO INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), PRECIGEN INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), ATHERSYS INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), VERASTEM INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), ANAPTYSBIO INC (NASDAQ), AGENUS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), XBIOTECH INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), MERUS B V (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), MACROGENICS INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), NANTKWEST INC (NASDAQ), KAMADA (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), PERSONALIS INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), NEUROINSIGHTS NEUROTECH (NASDAQ), SERES THERAPEUTICS (NASDAQ), GERON CORP (NASDAQ), ADURO BIOTECH INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), XOMA CORP (NASDAQ), VBI VACCINES INC CDA (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), RECRO PHARMA INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), CABALETTA BIO INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), IVERIC BIO INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), INFLARX N V (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), CHIASMA INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), MEDICINOVA INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), AFFIMED N V (NASDAQ), VAXART INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), CELYAD ADS EACH REPR 1 ORD (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), SAVARA INC (NASDAQ), IMV INC (NASDAQ), CHIMERIX INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), ARAVIVE INC (NASDAQ), CONTRAFECT CORP (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), VERMILLION INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), ORGENESIS INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), LUMOS PHARMA INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), VACCINEX INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), OTONOMY INC (NASDAQ), ANPAC BIO MEDICAL SCIENCE CO LTD SPON ADS EACH REPR 1 ORD SHS CLASS A (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), SESEN BIO INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), SYNLOGIC INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), COHBAR INC (NASDAQ), TREVENA INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), EQUILLIUM INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), SOLIGENIX INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), RESTORBIO INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), INMUNE BIO INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), ADVAXIS INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), ZAFGEN INC (NASDAQ), ATYR PHARMA INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), CURIS INC (NASDAQ), EVOGENE LTD (NASDAQ), TOCAGEN INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), BIOCARDIA INC (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), OCUGEN INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), AIKIDO PHARMA INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), SENECA BIOPHARMA INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 5 ORD SHS(R/S) (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), BENITEC BIOPHARMA LTD SPON ADS EA REPR 200 ORD SHS(POST SPLIT) (NASDAQ), PRECIPIO INC (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), SENESTECH INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ)
Global Peer CSL ASX 145,250.275 54.139 50.142 16.7950 0.829
Global Peer AMGEN-T HKEx 589,807.000 8.965 9.598 7.8255 4.417
Global Peer AGILENT TECHNOLOGIES INC NYSE 23,025.648 72.866 30.138 4.7495 0.823
Global Peer WUXI BIO HKEx 146,586.937 196.257 127.704 10.2504 -
Global Peer SINO BIOPHARM HKEx 134,607.872 12.563 43.732 3.8678 0.684
Global Peer BEIGENE HKEx 87,624.096 - - 11.6875 -
Global Peer Lonza SGX 5,937.453 6.613 6.613 0.6568 4.787
Global Peer EMERGENT BIOSOLUTIONS INC NYSE 2,998.320 47.820 54.914 2.7545 -
Global Peer GENSCRIPT BIO HKEx 23,175.513 139.381 - 7.7701 -
Global Peer 3SBIO HKEx 21,018.614 13.894 19.147 1.9522 -
Other Global Peers ALPHAMAB-B (HKEx), HAOHAI BIOTEC (HKEx), VIVA BIOTECH (HKEx), FRONTAGE (HKEx), MYOVANT SCIENCES LTD (NYSE), POLYNOVO LIMITED (ASX), ARCUS BIOSCIENCES INC (NYSE), KADMON HLDGS INC (NYSE), ASCENTAGE-B (HKEx), AVITA MEDICAL LTD (ASX), MESOBLAST LTD (ASX), ASCLETIS-B (HKEx), SINOMAB BIO-B (HKEx), NANOVIRICIDES INC (NYSE American), ESSEX BIO-TECH (HKEx), LEE'S PHARM (HKEx), BBI LIFE SCI (HKEx), DPHARMA (Bursa), PFENEX INC (NYSE American), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), TELIX PHARMACEUTIC (ASX), UNI-BIO GROUP (HKEx), NEXT SCIENCE LTD (ASX), ENZO BIOCHEM INC (NYSE), LINEAGE CELL THERAPEUTICS INC (NYSE American), CEL-SCI CORP (NYSE American), IBIO INC (NYSE American), AIM IMMUNOTECH INC (NYSE American), 22ND CENTURY GROUP INC (NYSE American), PALATIN TECHNOLOGIES INC (NYSE American), NEUREN PHARMACEUTICALS LTD (ASX), ARMATA PHARMACEUTICALS INC (NYSE American), IMUGENE LIMITED (ASX), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), BIOTRON (ASX), CYNATA THERAPEUTICS LTD (ASX), CT ENTERPRISE (HKEx), SYNTHETIC BIOLOGICS INC (NYSE American), BIOSINO BIO-TEC (HKEx), INVEX THERAPEUTICS LTD NPV (ASX), IMMUTEP LTD (ASX), ORAGENICS INC (NYSE American), HOLISTA COLLTECH LIMITED (ASX), KAZIA THERAPEUTICS LIMITED (ASX), MEMPHASYS LTD (ASX), ANTEOTECH LIMITED (ASX), Suntar Eco-City^ (SGX), REGENT PACIFIC (HKEx), ACTINIUM PHARMACEUTICALS INC (NYSE American), ACTINOGEN MEDICAL LTD (ASX), GENETIC TECHNOLOGIES (ASX), BIONOMICS LTD (ASX), INDIA GLOBALIZATION CAPITAL INC (NYSE American), CCP TECHNOLOGIES LTD (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), REGENEUS LTD (ASX), HAO WEN HLDGS (HKEx), PATRYS LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), RHINOMED LIMITED (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), SIENNA CANCER DIAGNOSTICS LTD (ASX), ANATARA LIFESCIENCES LTD (ASX), LEAF RESOURCES LTD (ASX), BENITEC BIOPHARMA LTD (ASX), ADALTA LTD (ASX), LIVING CELL TECHNOLOGIES (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), AUSTRALIAN PRIMARY HEMP LTD (ASX), CRYOSITE (ASX), FACTOR THERAPEUTICS LIMITED (ASX), NANOLLOSE LTD (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.140
-3.23 %
10 Days -+0.820
+24.26 %
20 Days --1.950
-31.71 %
Medium Term Return 3 Months --3.350
-44.37 %
6 Months --2.360
-35.98 %
1 Year --1.320
-23.91 %
Long Term Return 2 Years --1.350
-24.32 %
3 Years --5.990
-58.78 %
Annualised Return Annualised --
-25.58 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 3.120 - 10.880 Change From 1 Year Low +1.080 % Change From 1 Year Low (%) +34.61
Change From 1 Year High -6.680 % Change From 1 Year High (%) -61.40
2 Years Range 3.120 - 10.880 Change From 2 Years Low +1.080 % Change From 2 Years Low (%) +34.61
Change From 2 Years High -6.680 % Change From 2 Years High (%) -61.40
5 Years Range 3.120 - 12.500 Change From 5 Years Low +1.080 % Change From 5 Years Low (%) +34.61
Change From 5 Years High -8.300 % Change From 5 Years High (%) -66.40
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.

Historical Price Data

Date Open High Low Close Volume VWAP
03 Apr 2020 4.480 4.490 4.100 4.200 137,766 -
02 Apr 2020 4.680 4.680 4.360 4.520 110,097 -
01 Apr 2020 4.740 4.750 4.460 4.550 254,291 -
31 Mar 2020 4.490 4.490 4.210 4.380 162,022 -
30 Mar 2020 4.370 4.615 4.200 4.340 183,457 -
27 Mar 2020 4.140 4.210 3.840 4.050 110,119 -
26 Mar 2020 3.790 4.400 3.790 4.060 317,836 -
25 Mar 2020 3.810 3.830 3.660 3.680 121,572 -
24 Mar 2020 3.630 3.750 3.427 3.660 193,219 -
23 Mar 2020 3.520 3.520 3.120 3.380 255,573 -
20 Mar 2020 3.750 3.940 3.410 3.570 482,633 -
19 Mar 2020 4.040 4.040 3.520 3.710 489,926 -
18 Mar 2020 3.960 5.460 3.900 4.420 566,147 -
17 Mar 2020 4.050 4.150 3.860 4.040 321,560 -
16 Mar 2020 5.150 5.150 4.110 4.400 261,382 -
13 Mar 2020 5.090 5.800 5.000 5.250 236,884 -
12 Mar 2020 5.200 5.200 4.600 4.790 324,652 -
11 Mar 2020 6.200 6.390 5.974 6.025 237,714 -
10 Mar 2020 8.040 8.160 7.000 7.450 337,089 -
09 Mar 2020 6.750 6.760 6.150 6.150 183,121 -
06 Mar 2020 7.000 7.000 6.750 6.880 136,687 -
05 Mar 2020 7.700 7.700 7.065 7.160 77,998 -
Summary
Current 2 Weeks
(23 Mar 2020 to 03 Apr 2020)
3.520 4.750 3.120 4.200 1,845,952 -
Previous 2 Weeks
(09 Mar 2020 to 20 Mar 2020)
6.750 6.760 3.120 3.570 3,441,108 -
4 Weeks from
(07 Feb 2020 to 06 Mar 2020)
10.000 10.000 3.120 6.880 1,644,903 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.